Intravenous N-Acetylcysteine During Haemodialysis Reduces the Plasma Concentration of Homocysteine in Patients With End-Stage Renal Disease

Mochammad Thaha; Mohammad Yogiantoro; Yasuhiko Tomino


Clin Drug Invest. 2006;26(4):195-202. 

In This Article


This study further demonstrates that intravenous administration of N-acetylcysteine during haemodialysis normalises plasma homocysteine concentration, and that this is associated with improved pulse pressure. Reduction in excess cardiovascular risk is required in patients with end-stage renal failure. Together with evidence that binding of N-acetylcysteine to plasma nitric oxide has potentially beneficial effects on platelet aggregation, apoptosis and the atherosclerotic process, these findings suggest that intravenous administration of N-acetylcysteine during haemodialysis may be a promising novel approach to help reduce atherothrombotic risk in these vulnerable patients.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: